Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on November 27, 2015. The filing reports the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics and Agreement Terms
- Agreement Type: Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co.
- Maximum Offering Size: Up to $10,000,000 in aggregate offering price.
- Commission: 3.0% of aggregate gross proceeds from sales.
- Expense Reimbursement: Up to $50,000 for fees and expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Financial Performance: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
Material Changes
The primary material change is the establishment of an "at the market" equity offering program. The company is not obligated to sell any shares and may set minimum sales prices. Either party may terminate the agreement with ten days' prior notice.
Guidance, Outlook, and Risks
- Outlook: The company intends to use net proceeds for working capital, though no specific sales volume or timing is guaranteed.
- Risks: The agreement is subject to termination by either party. Sales are contingent on market conditions and the company's election to sell.
- Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $10 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination clauses and pricing mechanisms.
- Confirm the company's current cash position to assess the immediate necessity of this capital raise.
- Check subsequent filings to determine if any shares have actually been sold under this agreement.